Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 2021
Shots:
- The ongoing P-II AAVIATE & ALTITUDE trial evaluates RGX-314 using suprachoroidal delivery in patients with wet AMD & DR without CI-DME, respectively
- In the P-II AAVIATE trial, the therapy showed stable visual acuity & retinal thickness, >70% reduction in anti-VEGF treatment burden @6mos., 40% of patients were anti-VEGF inj.-free & was well tolerated in cohort 2. The results from cohort 1 in the P-II ALTITUDE trial showed stable visual acuity @3mos. after one-time treatment of RGX-314
- RGX-314 has developed with NAV AAV8 vector that encodes an Ab fragment & inhibits VEGF. The therapy is being investigated as a one-time treatment for wet AMD, DR & other chronic retinal conditions
Ref: PR Newswire | Image: Regenxbio
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com